Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05984394

Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease

Evaluation of Antigen-specific Th1 and T17 Cells, ILC and MAIT in Patients With Antisynthetase Syndrome and Interstitial Lung Disease

Status
Recruiting
Phase
Study type
Observational
Enrollment
24 (estimated)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Antisynthetase syndrome (AS) is a rare overlapping myositis characterized by cellular and humoral autoimmune responses directed against aminoacyl-tRNA synthetases. Intesrtitial lung disease (ILD) is a leading cause of mortality in antisynthetase syndrome. Recently, antigen-specific IFN-γ+ CD4+ T cells have been identified in bronchoalveolar fluid (BAL) of patients with antisynthetase syndrome and ILD. Elevated levels of IL1β, IL12, IL18, TNFα, IL17A, IL22 have also been detected in peripheral blood of AS patients, especially those with progressive ILD. Implication of innate lymphoid cells (ILC) and mucosal-associated invariant T cells (MAIT) have not yet been studied in patients with AS. Targeted therapies against Th1 and Th17 cells may represent a promising treatment in patients AS patients with ILD. Investigators suppose that antigen-specific Th1 and Th17 cells, ILC and MAIT at ILD diagnosis are associated with ILD severity at diagnosis and could predict treatment response at 6 months. The main objective is to study the correlation between BAL antigen-specific Th1 and Th17 cells at ILD diagnosis and clinical evolution after 6 months of treatment according to initial ILD severity.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBAL antigen-specific Th1 cells and Th17 cells, ILC and MAITBAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT

Timeline

Start date
2024-08-26
Primary completion
2025-10-31
Completion
2025-10-31
First posted
2023-08-09
Last updated
2024-08-27

Locations

6 sites across 1 country: France

Source: ClinicalTrials.gov record NCT05984394. Inclusion in this directory is not an endorsement.